Smart Technology Facilitated Patient-centered Venous Thromboembolism Management: A Multicenter Cohort Study
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 2,353
- 试验地点
- 1
- 主要终点
- VTE-related composite event
研究概览
简要总结
Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.
The objective of this study is to observe the long-term effect of mobile venous thromboembolism application (mVTEA) based patient-centered management of venous thromboembolism (VTE) on thromboprophylaxis, and establish a foundation of evidence for managing patients with high-risk VTE.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inpatients ≥18 years of age at admission;
- •At high-risk of VTE at discharge: Padua score ≥4 for medical patients and Caprini score ≥5 for surgical patients;
- •Signed informed consent.
排除标准
- •Diagnosis of VTE at discharge;
- •Mental disorder or combination of other serious diseases leading to incapacity for independent living;
- •Inability to use smartphones, computer tablets and other smart devices;
- •Being pregnant or breastfeeding;
- •Have participated in similar trials or are undergoing other clinical trials.
结局指标
主要结局
VTE-related composite event
时间窗: At 1-year follow-up
The primary outcome was the occurrence of VTE-related composite event at 1-year follow-up, which was defined as a composite of VTE, major bleeding, VTE-related hospitalization, and all-cause death.
次要结局
- VTE-KAP questionnaire score(At 3, 12, and 24-month follow-up)
- Generic quality of life(At 3, 12, and 24-month follow-up)
- New-onset of atrial fibrillation or atrial flutter(At 3, 6, 12, and 24-month follow-up)
- Major bleeding(At 3, 6, 12, and 24-month follow-up)
- Death(At 3, 6, 12, and 24-month follow-up)
- VTE events(At 3, 6, 12, and 24-month follow-up)
- VTE-related hospitalization(At 3, 6, 12, and 24-month follow-up)